🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "huge turning point" in the effort against superbug strains of the infection, according to health experts.

A Worldwide Health Concern

Gonorrhoea infections are escalating worldwide, with figures suggesting more than 82 million new cases each year. Especially elevated rates are observed in Africa and countries within the WHO's Western Pacific region, which encompasses China and Mongolia to New Zealand. Across England, cases have hit a all-time high, while figures across Europe in 2023 were triple the level compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an important and timely advancement in the context of increasing worldwide cases, increasing antimicrobial resistance and the highly restricted available drugs currently available.”

Health officials are increasingly worried about the increase in drug-resistant strains. The World Health Organization has classified it as a "high-priority threat". Recent surveillance found that the effectiveness of primary antibiotics like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

A Pair of Novel Drugs Gain Approval

One new antibiotic, marketed under the name a brand name, was authorized by the US FDA in December for use against gonorrhoea. This disease can lead to significant complications, including infertility. Researchers believe that targeted use of this new drug will help delay the development of resistance.

Another new antibiotic, created by the drugmaker GSK, also received approval in concurrent days. This treatment, which is employed against UTIs, was shown in trials to be successful in treating antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin emerged from a innovative non-profit model for medication research. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the drug firm its industry partner to see it through.

“This approval marks a major breakthrough in the therapy of highly resistant gonorrhoea, which until now has been outpacing medical innovation.”

Testing Results and Global Access

According to data detailed in a prominent scientific publication, zoliflodacin cured the vast majority of uncomplicated infections. This puts it on an comparable level with the typical regimen, which involves a dual-drug approach. The trial included hundreds of volunteers from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Doctors directly involved have shared positive views. The availability of a single-dose, oral treatment such as this is hailed as a "critical tool" for public health efforts. This is considered essential to reduce the burden of the disease for people and to prevent the spread of extremely resistant gonorrhoea worldwide.